Fig. 2From: Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trialsPlasma concentration–time profiles from the first dose to 4 weeks with MTX (A) and trough concentrations throughout 52 weeks with or without MTX (B). Data are expressed as mean ± standard deviation. MTX methotrexateBack to article page